Brimonidine

• Description:

  Brimonidine (UK 14304) is a full α2-adrenergic receptor (α2-AR) agonist.

• Product Name Alternative:

  UK 14304; AGN190342

• UNSPSC:

  12352005

• Hazard Statement:

  H301

• Target:

  Adrenergic Receptor

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein; Neuronal Signaling

• Field of Research:

  Endocrinology; Cancer; Cardiovascular Disease

• Assay Protocol:

  https://www.medchemexpress.com/uk-14,304.html

• Purity:

  99.98

• Solubility:

  DMSO : 50 mg/mL (ultrasonic)

• Smiles:

  BrC1=C2N=CC=NC2=CC=C1NC3=NCCN3

• Molecular Formula:

  C11H10BrN5

• Molecular Weight:

  292.13

• Precautions:

  H301

• References & Citations:

  [1]Andorn, A.C., M.A. Carlson, and R.C. Gilkeson, Specific [3H]UK 14,304 binding in human cortex occurs at multiple high affinity states with alpha 2-adrenergic selectivity and differing affinities for GTP. Life Sci, 1988. 43 (22) : p. 1805-12.|[2]Cambridge, D., UK-14,304, a potent and selective alpha2-agonist for the characterisation of alpha-adrenoceptor subtypes. Eur J Pharmacol, 1981. 72 (4) : p. 413-5.|[3]Chopin, P., F.C. Colpaert, and M. Marien, Effects of alpha-2 adrenoceptor agonists and antagonists on circling behavior in rats with unilateral 6-hydroxydopamine lesions of the nigrostriatal pathway. J Pharmacol Exp Ther, 1999. 288 (2) : p. 798-804.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Launched

• Isoform:

  α adrenergic receptor

• Citation 01:

  Anal Chem. 2025 Jun 3;97 (21) :11099-11109.|Nat Biomed Eng. 2025 Apr 30.|Cell Rep. 2019 Dec 3;29 (10) :2929-2935.e4|Int J Pharm. 2022 Feb 5:613:121361.|J Ocul Pharmacol Ther. 2023 Sep;39 (7) :456-462.|J Ocul Pharmacol Ther. 2025 Sep 18.

• CAS Number:

  [59803-98-4]